| Drug Name |
Pralatrexate |
| Drug ID |
BADD_D01814 |
| Description |
Pralatrexate is an antimetabolite for the treatment of relapsed or refractory peripheral T-cell lymphoma. It is more efficiently retained in cancer cells than methotrexate. FDA approved on September 24, 2009. |
| Indications and Usage |
Treatment of relapsed or refractory peripheral T-cell lymphoma. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01BA05 |
| DrugBank ID |
DB06813
|
| KEGG ID |
D05589
|
| MeSH ID |
C418863
|
| PubChem ID |
148121
|
| TTD Drug ID |
D02LWU
|
| NDC Product Code |
72893-005; 47848-045; 53183-4020; 48818-001; 65219-550; 72893-003; 68554-0071; 65219-552; 65392-2510 |
| UNII |
A8Q8I19Q20
|
| Synonyms |
10-propargyl-10-deazaaminopterin | pralatrexate |
